CU23792A3 - Novedosos anticuerpos antiproliferación - Google Patents

Novedosos anticuerpos antiproliferación

Info

Publication number
CU23792A3
CU23792A3 CU20090082A CU20090082A CU23792A3 CU 23792 A3 CU23792 A3 CU 23792A3 CU 20090082 A CU20090082 A CU 20090082A CU 20090082 A CU20090082 A CU 20090082A CU 23792 A3 CU23792 A3 CU 23792A3
Authority
CU
Cuba
Prior art keywords
antibodies
new
present
antiproliferation antibodies
antiproliferation
Prior art date
Application number
CU20090082A
Other languages
English (en)
Inventor
Cedric Bes
Jean-Francois Haeuw
Nathalie Corvaia
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CU23792A3 publication Critical patent/CU23792A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención está relacionada con anticuerpos aislados novedosos, o los compuestos derivados o fragmentos funcionales de los mismos, capaces de inhibir la proliferación de células tumorales in vitro y/o in vivo, dichos anticuerpos han sido obtenidos por tamizado funcional. Más particularmente, la presente invención se relaciona con el anticuerpo 6F4, específico para la proteína JAM-A, como así también con su uso para el tratamiento del cáncer. También están cubiertas las composiciones farmacéuticas compuestas por tales anticuerpos.
CU20090082A 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferación CU23792A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
CU23792A3 true CU23792A3 (es) 2012-03-15

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090082A CU23792A3 (es) 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferación

Country Status (28)

Country Link
US (2) US8071730B2 (es)
EP (1) EP2074148A1 (es)
JP (1) JP2010509931A (es)
KR (1) KR20090088878A (es)
CN (1) CN101535344B (es)
AU (1) AU2007324509B2 (es)
BR (1) BRPI0719323A2 (es)
CA (1) CA2670039A1 (es)
CL (1) CL2007003357A1 (es)
CR (1) CR10788A (es)
CU (1) CU23792A3 (es)
EC (1) ECSP099341A (es)
FR (1) FR2909092B1 (es)
GE (1) GEP20125629B (es)
GT (1) GT200900126A (es)
HK (1) HK1132752A1 (es)
IL (1) IL198744A0 (es)
MA (1) MA30891B1 (es)
MX (1) MX2009005293A (es)
NI (1) NI200900079A (es)
NO (1) NO20092360L (es)
NZ (1) NZ576174A (es)
RU (1) RU2451689C2 (es)
SA (1) SA07280637B1 (es)
TN (1) TN2009000194A1 (es)
TW (1) TW200829602A (es)
UA (1) UA99602C2 (es)
WO (1) WO2008062063A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
JP2013509191A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
EA201390472A1 (ru) * 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
BR112018067522A2 (pt) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CN109789197A (zh) * 2016-08-03 2019-05-21 奈斯科尔公司 用于调节lair信号转导的组合物和方法
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
ES2364266T3 (es) * 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
US7981628B2 (en) * 2006-04-28 2011-07-19 Oregon Health & Science University Monoclonal antibodies and their use

Also Published As

Publication number Publication date
CN101535344A (zh) 2009-09-16
US20120156191A1 (en) 2012-06-21
MA30891B1 (fr) 2009-11-02
FR2909092B1 (fr) 2012-10-19
CL2007003357A1 (es) 2008-04-04
BRPI0719323A2 (pt) 2014-02-04
RU2009123409A (ru) 2010-12-27
GEP20125629B (en) 2012-09-10
CN101535344B (zh) 2013-10-16
TN2009000194A1 (en) 2010-10-18
MX2009005293A (es) 2009-08-07
NI200900079A (es) 2010-11-10
FR2909092A1 (fr) 2008-05-30
IL198744A0 (en) 2010-02-17
NZ576174A (en) 2012-03-30
EP2074148A1 (en) 2009-07-01
WO2008062063A1 (en) 2008-05-29
US20100092455A1 (en) 2010-04-15
TW200829602A (en) 2008-07-16
SA07280637B1 (ar) 2012-04-11
CR10788A (es) 2009-06-23
ECSP099341A (es) 2009-06-30
UA99602C2 (ru) 2012-09-10
US8071730B2 (en) 2011-12-06
JP2010509931A (ja) 2010-04-02
RU2451689C2 (ru) 2012-05-27
AU2007324509B2 (en) 2013-01-17
NO20092360L (no) 2009-08-11
CA2670039A1 (en) 2008-05-29
GT200900126A (es) 2011-09-02
HK1132752A1 (en) 2010-03-05
AU2007324509A1 (en) 2008-05-29
KR20090088878A (ko) 2009-08-20

Similar Documents

Publication Publication Date Title
NI200900079A (es) Novedosos anticuerpos antiproliferación.
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BR112012013664A2 (pt) rabdovírus oncolítico
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
GT200500237A (es) Derivados de pirimidina
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201390010A1 (ru) Замещенные триазолопиридины
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)